Previous studies with limited sample sizes have indicated a link between mitochondrial traits, inflammatory proteins, and Alzheimer's disease. The exact causality and their mediation relationships remain unclear.
Objective
Our study aimed to delve into the genetic underpinnings of mitochondrial function and circulating inflammatory proteins in the pathogenesis of Alzheimer's disease.
Methods
We leveraged aggregated data from the largest genome-wide association study, including 69 mitochondrial traits, 91 circulating inflammatory proteins, and Alzheimer's disease. Bidirectional mendelian randomization (MR) analyses were performed to investigate their primary causal relationships. Thereafter a two-step MR mediation analysis was utilized to clarify the modulating effects of inflammatory proteins on mitochondria and Alzheimer's disease.
Results
Our study identified mitochondrial phenylalanine-tRNA ligase and 4-hydroxy-2-oxoglutarate aldolase as risk factors for Alzheimer's disease, and serine protease HtrA2 and carbonic anhydrase 5A as protective factors against Alzheimer's disease. Four inflammatory proteins (T-cell surface glycoprotein CD5, C-X-C motif chemokine 11, TGF-α, and TNF-related apoptosis-inducing ligand) played protective roles against Alzheimer's disease. Axin-1 and IL-6 increased the risk of Alzheimer's disease. Furthermore, T-cell surface glycoprotein CD5 was found to be a significant mediator between mitochondrial serine protease HTRA2 and Alzheimer's disease with the two-step MR method, accounting for 10.83% of the total effect.
Conclusions
Our study emphasized mitochondrial HtrA2-T cell CD5 as a negative axis in Alzheimer's disease, offering novel perspectives on its etiology, pathogenesis, and treatment.
AtriA. The Alzheimer's disease clinical spectrum: Diagnosis and management. Med Clin North Am2019; 103: 263–293.
2.
World Health Organization. Global status report on the public health response to dementia. Geneva: World Health Organization, 2021.
3.
VillemagneVLBurnhamSBourgeatP, et al.Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol2013; 12: 357–367.
4.
ZhangHWeiWZhaoM, et al.Interaction between Aβ and tau in the pathogenesis of Alzheimer's disease. Int J Biol Sci2021; 17: 2181–2192.
5.
PanzaFLozuponeMLogroscinoG, et al.A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease. Nat Rev Neurol2019; 15: 73–88.
6.
JeremicDJimenez-DiazLNavarro-LopezJD. Past, present and future of therapeutic strategies against amyloid-beta peptides in Alzheimer's disease: a systematic review. Ageing Res Rev2021; 72: 101496.
7.
LianYJiaYJWongJ, et al.Clarity on the blazing trail: Clearing the way for amyloid-removing therapies for Alzheimer's disease. Mol Psychiatry2024; 29: 297–305.
8.
SongTSongXZhuC, et al.Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer's disease: A meta-analysis of in vivo magnetic resonance spectroscopy studies. Ageing Res Rev2021; 72: 101503.
9.
SongNMeiSWangX, et al.Focusing on mitochondria in the brain: from biology to therapeutics. Transl Neurodegener2024; 13: 23.
10.
AshleighTSwerdlowRHBealMF. The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis. Alzheimers Dement2023; 19: 333–342.
11.
BoccardiVComanducciCBaroniM, et al.Of energy and entropy: The ineluctable impact of aging in old age dementia. Int J Mol Sci2017; 18: 2672.
12.
HanXJHuYYYangZJ, et al.Amyloid β-42 induces neuronal apoptosis by targeting mitochondria. Mol Med Rep2017; 16: 4521–4528.
13.
Ahumada-CastroUPuebla-HuertaACuevas-EspinozaV, et al.Keeping zombies alive: The ER-mitochondria Ca(2+) transfer in cellular senescence. Biochim Biophys Acta Mol Cell Res2021; 1868: 119099.
14.
DewanjeeSChakrabortyPBhattacharyaH, et al.Altered glucose metabolism in Alzheimer's disease: Role of mitochondrial dysfunction and oxidative stress. Free Radic Biol Med2022; 193: 134–157.
15.
HeavenerKSBradshawEM. The aging immune system in Alzheimer's and Parkinson's diseases. Semin Immunopathol2022; 44: 649–657.
16.
LiYLiuLBargerSW, et al.Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci2003; 23: 1605–1611.
ShanCZhangCZhangC. The role of IL-6 in neurodegenerative disorders. Neurochem Res2024; 49: 834–846.
19.
WangHYeJPengY, et al.CKLF induces microglial activation via triggering defective mitophagy and mitochondrial dysfunction. Autophagy2024; 20: 590–613.
20.
XiaXHeXZhaoT, et al.Inhibiting mtDNA-STING-NLRP3/IL-1beta axis-mediated neutrophil infiltration protects neurons in Alzheimer's disease. Cell Prolif2024; 57: e13529.
21.
ChuJZhangWLiuY, et al.Biomaterials-based anti-inflammatory treatment strategies for Alzheimer's disease. Neural Regen Res2024; 19: 100–115.
22.
FangEFHouYPalikarasK, et al.Mitophagy inhibits amyloid-beta and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. Nat Neurosci2019; 22: 401–412.
23.
LautrupSLouGAmanY, et al.Microglial mitophagy mitigates neuroinflammation in Alzheimer's disease. Neurochem Int2019; 129: 104469.
24.
HickmanSEAllisonEKEl KhouryJ. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci2008; 28: 8354–8360.
25.
DhapolaRHotaSSSarmaP, et al.Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer's disease. Inflammopharmacology2021; 29: 1669–1681.
26.
GreenDRGalluzziLKroemerG. Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science2011; 333: 1109–1112.
27.
BurgessSDavey SmithGDaviesNM, et al.Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Res2019; 4: 186.
28.
YinKFChenTGuXJ, et al.Identification of potential causal genes for neurodegenerative diseases by mitochondria-related genome-wide Mendelian randomization. Mol Neurobiol2025; 62: 3892–3902.
29.
SkrivankovaVWRichmondRCWoolfBAR, et al.Strengthening the reporting of observational studies in epidemiology using mendelian randomization: The STROBE-MR statement. JAMA2021; 326: 1614–1621.
30.
SunBBMaranvilleJCPetersJE, et al.Genomic atlas of the human plasma proteome. Nature2018; 558: 73–79.
31.
GillyAParkYCPngG, et al.Whole-genome sequencing analysis of the cardiometabolic proteome. Nat Commun2020; 11: 6336.
32.
ZhaoJHStaceyDErikssonN, et al.Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nat Immunol2023; 24: 1540–1551.
33.
BellenguezCKucukaliFJansenIE, et al.New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet2022; 54: 412–436.
BurgessS. Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome. Int J Epidemiol2014; 43: 922–929.
36.
HemaniGZhengJElsworthB, et al.The MR-Base platform supports systematic causal inference across the human phenome. Elife2018; 7: e34408.
37.
BowdenJDavey SmithGHaycockPC, et al.Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol2016; 40: 304–314.
38.
ReltonCLDavey SmithG. Two-step epigenetic Mendelian randomization: a strategy for establishing the causal role of epigenetic processes in pathways to disease. Int J Epidemiol2012; 41: 161–176.
39.
YinKFGuXJSuWM, et al.Causal association and mediating effect of blood biochemical metabolic traits and brain image-derived endophenotypes on Alzheimer's disease. Heliyon2024; 10: e27422.
40.
VanderWeeleTJ. Mediation analysis: A practitioner's guide. Annu Rev Public Health2016; 37: 17–32.
41.
SmithGDLawlorDAHarbordR, et al.Clustered environments and randomized genes: a fundamental distinction between conventional and genetic epidemiology. PLoS Med2007; 4: e352.
42.
JohnsonABBlumNR. Nucleoside phosphatase activities associated with the tangles and plaques of Alzheimer's disease: A histochemical study of natural and experimental neurofibrillary tangles. J Neuropathol Exp Neurol1970; 29: 463–478.
43.
ManczakMCalkinsMJReddyPH. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: Implications for neuronal damage. Hum Mol Genet2011; 20: 2495–2509.
44.
MutisyaEMBowlingACBealMF. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem1994; 63: 2179–2184.
45.
RiedelTJKnightJMurrayMS, et al.4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. Biochim Biophys Acta2012; 1822: 1544–1552.
46.
DeanRTFuSStockerR, et al.Biochemistry and pathology of radical-mediated protein oxidation. Biochem J1997; 324(Pt 1): 1–18.
47.
JohriA. Disentangling mitochondria in Alzheimer's disease. Int J Mol Sci2021; 22: 11520.
48.
KlipcanLMoorNKesslerN, et al.Eukaryotic cytosolic and mitochondrial phenylalanyl-tRNA synthetases catalyze the charging of tRNA with the meta-tyrosine. Proc Natl Acad Sci U S A2009; 106: 11045–11048.
49.
Vande WalleLLamkanfiMVandenabeeleP. The mitochondrial serine protease HtrA2/Omi: an overview. Cell Death Differ2008; 15: 453–460.
50.
Darreh-ShoriTRezaeianyazdiSLanaE, et al.Increased active OMI/HTRA2 serine protease displays a positive correlation with cholinergic alterations in the Alzheimer's disease brain. Mol Neurobiol2019; 56: 4601–4619.
51.
MoisoiNKlupschKFedeleV, et al.Mitochondrial dysfunction triggered by loss of HtrA2 results in the activation of a brain-specific transcriptional stress response. Cell Death Differ2009; 16: 449–464.
52.
MartinsLMMorrisonAKlupschK, et al.Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol2004; 24: 9848–9862.
53.
AspatwarASupuranCTWaheedA, et al.Mitochondrial carbonic anhydrase VA and VB: properties and roles in health and disease. J Physiol2023; 601: 257–274.
54.
GhandourMSParkkilaAKParkkilaS, et al.Mitochondrial carbonic anhydrase in the nervous system: expression in neuronal and glial cells. J Neurochem2000; 75: 2212–2220.
SharifALegendrePPrévotV, et al.Transforming growth factor α promotes sequential conversion of mature astrocytes into neural progenitors and stem cells. Oncogene2007; 26: 2695–2706.
61.
BlumM. A null mutation in TGF-α leads to a reduction in midbrain dopaminergic neurons in the substantia nigra. Nature Neuroscience1998; 1: 374–377.
62.
GencSEgrilmezMYYakaE, et al.TNF-related apoptosis-inducing ligand level in Alzheimer's disease. Neurol Sci2009; 30: 263–267.
63.
CantarellaGUbertiDCarsanaT, et al.Neutralization of TRAIL death pathway protects human neuronal cell line from beta-amyloid toxicity. Cell Death Differ2003; 10: 134–141.
64.
IkedaTHirataSFukushimaS, et al.Dual effects of TRAIL in suppression of autoimmunity: the inhibition of Th1 cells and the promotion of regulatory T cells. J Immunol2010; 185: 5259–5267.
65.
KrutsenkoYSinghiADMongaSP. β-catenin activation in hepatocellular cancer: Implications in biology and therapy. Cancers (Basel)2021; 13: 1830.
66.
MartinezMInestrosaNC. The transcriptional landscape of Alzheimer's disease and its association with Wnt signaling pathway. Neurosci Biobehav Rev2021; 128: 454–466.
67.
YangRDuanJLuoF, et al.IL-6, IL-8 and IL-10 polymorphisms may impact predisposition of Alzheimer's disease: A meta-analysis. Acta Neurol Belg2021; 121: 1505–1512.
68.
CalsolaroVEdisonP. Neuroinflammation in Alzheimer's disease: Current evidence and future directions. Alzheimers Dement2016; 12: 719–732.
69.
Rodriguez-NuevoAZorzanoA. The sensing of mitochondrial DAMPs by non-immune cells. Cell Stress2019; 3: 195–207.
70.
TiganoMVargasDCTremblay-BelzileS, et al.Nuclear sensing of breaks in mitochondrial DNA enhances immune surveillance. Nature2021; 591: 477–481.
LiHBurgueno-BucioEXuS, et al.CD5 on dendritic cells regulates CD4+ and CD8+ T cell activation and induction of immune responses. PLoS One2019; 14: e0222301.
73.
MatsonCAChoiSLivakF, et al.CD5 dynamically calibrates basal NF-kappaB signaling in T cells during thymic development and peripheral activation. Proc Natl Acad Sci U S A2020; 117: 14342–14353.
74.
UsluSAkarkarasuZEOzbabalikD, et al.Levels of amyloid beta-42, interleukin-6 and tumor necrosis factor-alpha in Alzheimer's disease and vascular dementia. Neurochem Res2012; 37: 1554–1559.
75.
ZhangYLiDZhuZ, et al.Evaluating the impact of metformin targets on the risk of osteoarthritis: a mendelian randomization study. Osteoarthritis Cartilage2022; 30: 1506–1514.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
